Key result
Anti-TNF therapy in patients with rheumatoid arthritis was not associated with a increased overall risk of serious infection compared to traditional DMARDs.
Why the study?
Observational data assessing infection risk with anti-TNF therapy in RA are subject to biases regarding treatment timing and duration, prompting this evaluation of how these biases and analytical methods influence infection risk.
Does anti-TNFα therapy increase the risk of serious infection in patients with rheumatoid arthritis compared to traditional DMARDs?
Observational (n=10,755)
Yes
Does anti-TNFα therapy increase the risk of serious infection in patients with rheumatoid arthritis compared to traditional DMARDs?
The apparent lack of overall increased infection risk with anti-TNFα therapy in RA is heavily influenced by selection biases in starting and stopping therapy, masking a true increased risk early in treatment.
Answers are grounded in this paper and cite their sources.
Reassures on overall serious infection risk with anti-TNF versus DMARDs in RA; leaves open early-treatment hazard due to selection biases.
Objective.In a recent observational study, we found that the risk of serious infection following antitumor necrosis factor ␣ (anti-TNF␣) therapy in patients with rheumatoid arthritis (RA) was not importantly increased compared with the background risk in routinely treated RA patients with similar disease severity.Observational data sets are, however, subject to a number of important biases related to selection factors for the timing of starting and stopping therapy.Infection risk is also likely to vary with duration of therapy.This study was undertaken to examine the influences of these biases and of the method of analysis on the risk of infection.Methods.We compared the risk of serious infection in 8,659 patients treated with anti-TNF␣ with that in 2,170 patients treated with traditional diseasemodifying antirheumatic drugs (DMARDs) recruited to the British Society for Rheumatology Biologics Register.We applied a number of statistical models in which we varied the length of the followup period by using different definitions of the date of discontinuation of treatment and different lag periods of risk following drug cessation.Results.When the at-risk period was defined as "receiving treatment", the adjusted incidence rate ratio comparing patients receiving anti-TNF␣ therapy with patients receiving DMARD therapy was 1.22 (95% confidence interval [95% CI] 0.88-1.69).Limiting followup to the first 90 days, however, revealed an adjusted incidence rate ratio of 4.6 (95% CI 1.8-11.9).Rates of infection were increased in the 90 days immediately following drug discontinuation and beyond, explained by selection factors for drug discontinuation.Conclusion.These findings show that overall, the way in which UK rheumatologists select patients for starting and discontinuing anti-TNF␣ therapy explains our previous finding of no increase in risk.However, there may be important increases in true risk, notably early in the course of treatment, that would become more evident depending on the definition of at-risk period.There are currently 3 anti-tumor necrosis factor ␣ (anti-TNF␣) drugs licensed for use in rheumatoid arthritis (RA) in the UK: infliximab and adalimumab, both monoclonal antibodies, and etanercept, a TNF␣ receptor fusion protein.Since TNF␣ is involved in host defense and tumor surveillance, there have been concerns that anti-TNF␣ therapy might lead to adverse
No takes yet. Share an insight, caveat, or question.
Grillo et al. (2023) conducted an observational in Rheumatoid arthritis (n=10,755). Anti-TNF therapy vs. Traditional DMARDs was evaluated on Serious infection (leading to death, hospitalization, or requiring intravenous antibiotics) while receiving treatment (adjusted incidence rate ratio 1.22, 95% CI 0.88-1.69). Anti-TNF therapy in patients with rheumatoid arthritis was not associated with a increased overall risk of serious infection compared to traditional DMARDs.
Synapse has enriched 10 related papers. Consider them for comparative context: